AIP
SPRY icon

Ameritas Investment Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Ameritas Investment Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.3K Hold
4,888
– – ﹤0.01% 2239
2025
Q4 		$56.9K Sell
4,888
-710
-13% -$6.91K ﹤0.01% 2035
2025
Q3 		$56.3K Hold
5,598
– – ﹤0.01% 2044
2025
Q2 		$97.7K Buy
5,598
+777
+16% +$11.2K ﹤0.01% 1777
2025
Q1 		$60.6K Hold
4,821
– – ﹤0.01% 1994
2024
Q4 		$50.9K Hold
4,821
– – ﹤0.01% 2172
2024
Q3 		$69.9K Hold
4,821
– – ﹤0.01% 1996
2024
Q2 		$41K Buy
4,821
+2,819
+141% +$25K ﹤0.01% 2246
2024
Q1 		$20.5K Hold
2,002
– – ﹤0.01% 2554
2023
Q4 		$11K Hold
2,002
– – ﹤0.01% 2819
2023
Q3 		$7.57K Hold
2,002
– – ﹤0.01% 2907
2023
Q2 		$13.4K Buy
+2,002
New +$13.4K ﹤0.01% 2780
2022
Q2 		– Sell
-1,032
Closed -$4K – 3222
2022
Q1 		$4K Hold
1,032
– – ﹤0.01% 3007
2021
Q4 		$7K Hold
1,032
– – ﹤0.01% 2993
2021
Q3 		$10K Hold
1,032
– – ﹤0.01% 2941
2021
Q2 		$32K Hold
1,032
– – ﹤0.01% 2469
2021
Q1 		$45K Buy
+1,032
New +$48.8K ﹤0.01% 2147

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ameritas Investment Partners's SPRY Position: Q1 2026 in Review

Ameritas Investment Partners held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 4,888 shares worth $39.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2239.

Ameritas Investment Partners first reported a position in SPRY in Q1 2021 and has held it in 17 quarters since. The position peaked at $97.7K in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Ameritas Investment Partners held 4,888 shares of ARS Pharmaceuticals worth $39.3K as of Q1 2026.
  • Ameritas Investment Partners left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2239 holding.
  • Ameritas Investment Partners first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
  • Ameritas Investment Partners's ARS Pharmaceuticals position peaked at $97.7K in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.